Emmaus Life Sciences, Inc. (EMMA) Form 10-Q — May 15, 2026
Emmaus Life Sciences reported a net loss of $3.3 million for Q1 2026, driven by a 18% decline in revenue to $2.0 million as generic competition from ANI Pharmaceuticals erodes sales of its sole product, Endari. The company faces severe liquidity constraints, holding only $1.1 million in cash against a $64.5 million working capital deficit, leading management to disclose substantial doubt about its ability to continue as a going concern. To address immediate cash needs, Emmaus entered into a Sale of Future Receipts Agreement with Breeze Funding, selling $1.69 million of future receivables for $1.21 million in cash.
Key figures
- Revenue
- 1982000
- Total Debt
- 86556000
- Cash Position
- 1072000
- Shares outstanding
- 70188263
- Accumulated deficit
- 273402000
- Factoring purchase price
- 1210000
- Nit upfront fee received
- 3000000
- Factoring purchased amount
- 1692790
- Telcon bond offset q1 2026
- 2600000
Price after filing
Close on the filing date to close N calendar days later (from $0.01). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.